Allos Therapeutics, Inc – Product Pipeline Review – Q1 2011

Document Sample
Allos Therapeutics, Inc – Product Pipeline Review – Q1 2011 Powered By Docstoc
					    Allos Therapeutics, Inc – Product Pipeline Review –
                          Q1 2011
                                                                                          Reference Code: GMDHC1208CDB

                                                                                                Publication Date: MAY 2011




Allos Therapeutics, Inc – Product Pipeline Review – Q1 2011                                 GMDHC1208CDB / Published MAY 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Allos Therapeutics, Inc – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Allos Therapeutics, Inc Snapshot                                                                                      5
    Allos Therapeutics, Inc Overview                                                                                  5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Allos Therapeutics, Inc – Research and Development Overview                                                           6
    Key Therapeutic Areas                                                                                             6
Allos Therapeutics, Inc – Pipeline Review                                                                             9
    Pipeline Products by Stage of Development                                                                         9
    Pipeline Products – Monotherapy                                                                                  10
    Pipeline Products – Combination Treatment Modalities                                                             11
Allos Therapeutics, Inc – Pipeline Products Glance                                                                   12
    Allos Therapeutics, Inc – Late Stage Pipeline                                                                    12
         Registration Filed Products/Combination Treatment Modalities                                                12
    Allos Therapeutics, Inc Clinical Stage Pipeline Products                                                         13
         Phase II Products/Combination Treatment Modalities                                                          13
         Phase I Products/Combination Treatment Modalities                                                           14
Allos Therapeutics, Inc – Drug Profiles                                                                              15
    Folotyn                                                                                                          15
         Product Description                                                                                         15
         Mechanism of Action                                                                                         15
         R&D Progress                                                                                                15
    Carboplatin + Efaproxiral + Paclitaxel + Radiation Therapy                                                       17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    FOLOTYN + Gemcitabine Hydrochloride                                                                              19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    RH-1                                                                                                             20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
Allos Therapeutics, Inc – Pipeline Analysis                                                                          21
    Allos Therapeutics, Inc – Pipeline Products by Therapeutic Class                                                 21
    Allos Therapeutics, Inc - Pipeline Products By Target                                                            22
    Allos Therapeutics, Inc – Pipeline Products by Route of Administration                                           23
    Allos Therapeutics, Inc – Pipeline Products by Molecule Type                                                     24
Allos Therapeutics, Inc – Recent Pipeline Updates                                                                    25
Allos Therapeutics, Inc - Discontinued Pipeline Products                                                             27
    Discontinued Pipeline Product Profiles                                                                           27
         Cisplatin + Gemcitabine + Efaproxiral + Radiation Therapy                                                   27
         Cisplatin + Vinorelbine + Efaproxiral + Radiation Therapy                                                   28




Allos Therapeutics, Inc – Product Pipeline Review – Q1 2011                               GMDHC1208CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Allos Therapeutics, Inc – Product Pipeline Review



         RH-1                                                                                                        28
         RSR13 + Radiation Therapy                                                                                   29
Allos Therapeutics, Inc – Company Statement                                                                          30
Allos Therapeutics, Inc – Locations And Subsidiaries                                                                 32
    Head Office                                                                                                      32
    Other Locations & Subsidiaries                                                                                   32
Financial Deals Landscape                                                                                            33
    Allos Therapeutics, Inc, Deals Volume Summary, 2004 to YTD 2011                                                  33
    Allos Therapeutics, Inc, Deals Summary By Region, 2004 to YTD 2011                                               34
    Allos Therapeutics, Inc, Deals Summary, 2004 to YTD 2011                                                         35
    Allos Therapeutics, Inc Detailed Deal Summary                                                                    36
         Equity Offering                                                                                             36
         Allos Therapeutics Completes Public Offering Of $99 Million                                                 36
         Allos Therapeutics Completes Public Offering Of $49 Million                                                 38
         Allos Therapeutics Completes Public Offering Of $70.05 Million                                              40
         Allos Therapeutics Completes Public Offering Of $54 Million                                                 42
         Allos Therapeutics Completes Private Placement Of Preferred Stock                                           44
         Allos Therapeutics Enters Into Co-Development Agreement With Idis                                           46
Appendix                                                                                                             47
    Methodology                                                                                                      47
         Coverage                                                                                                    47
         Secondary Research                                                                                          47
         Primary Research                                                                                            47
         Expert Panel Validation                                                                                     48
    Contact Us                                                                                                       48
    Disclaimer                                                                                                       48




Allos Therapeutics, Inc – Product Pipeline Review – Q1 2011                               GMDHC1208CDB / Published MAY 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(3)
Allos Therapeutics, Inc – Product Pipeline Review




Lis t o f Ta b le s
Allos Therapeutics, Inc – Pipeline by Therapy Area and Indication, 2011                                                                                                                        8

Allos Therapeutics, Inc – Pipeline by Stage of Development, 2011                                                                                                                               9

Allos Therapeutics, Inc – Monotherapy Products in Pipeline, 2011                                                                                                                             10

Allos Therapeutics, Inc – Combination Treatment Modalities in Pipeline, 2011                                                                                                                 11

Allos Therapeutics, Inc – Filed, 2011                                                                                                                                                        12

Allos Therapeutics, Inc - Phase II, 2011                                                                                                                                                     13

Allos Therape
				
DOCUMENT INFO
Description: Allos Therapeutics, Inc – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Allos Therapeutics, Inc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Allos Therapeutics, Inc - Brief company overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Allos Therapeutics, Inc human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Allos Therapeutics, Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Allos Therapeutics, Inc’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Allos Therapeutics, Inc’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Allos Therapeutics, Inc in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Allos Therapeutics, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensi
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries